A pooled analysis of data from the FORWARD-I phase II study was announced to show a consistent clinical profile of mirvetuximab soravtansine with an overall response rate (ORR) of 47% and a progression free survival (PFS) of 6.7 months in 36 patients. The data meets the eligibility criteria for enrolment in the phase III FORWARD I study. Data from the FORWARD-II combinations studies, though early, also looked favorable. An approval of mirvetuximab soravtansine would be a huge boost for ImmunoGen, given the immense commercial potential in the target market.